Cargando…
Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases
Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684400/ https://www.ncbi.nlm.nih.gov/pubmed/34934338 http://dx.doi.org/10.2147/JIR.S276986 |
_version_ | 1784617611730878464 |
---|---|
author | Anyfanti, Panagiota Dara, Athanasia Angeloudi, Elena Bekiari, Eleni Dimitroulas, Theodoros Kitas, George D |
author_facet | Anyfanti, Panagiota Dara, Athanasia Angeloudi, Elena Bekiari, Eleni Dimitroulas, Theodoros Kitas, George D |
author_sort | Anyfanti, Panagiota |
collection | PubMed |
description | Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach. |
format | Online Article Text |
id | pubmed-8684400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86844002021-12-20 Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases Anyfanti, Panagiota Dara, Athanasia Angeloudi, Elena Bekiari, Eleni Dimitroulas, Theodoros Kitas, George D J Inflamm Res Review Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach. Dove 2021-12-14 /pmc/articles/PMC8684400/ /pubmed/34934338 http://dx.doi.org/10.2147/JIR.S276986 Text en © 2021 Anyfanti et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Anyfanti, Panagiota Dara, Athanasia Angeloudi, Elena Bekiari, Eleni Dimitroulas, Theodoros Kitas, George D Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title | Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title_full | Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title_fullStr | Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title_full_unstemmed | Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title_short | Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases |
title_sort | monitoring and managing cardiovascular risk in immune mediated inflammatory diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684400/ https://www.ncbi.nlm.nih.gov/pubmed/34934338 http://dx.doi.org/10.2147/JIR.S276986 |
work_keys_str_mv | AT anyfantipanagiota monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases AT daraathanasia monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases AT angeloudielena monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases AT bekiarieleni monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases AT dimitroulastheodoros monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases AT kitasgeorged monitoringandmanagingcardiovascularriskinimmunemediatedinflammatorydiseases |